Search Result

Isoforms Recommended:	EAAT2

Results for "

EAAT2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	EAAT (25) ASCT (3) Bcl-2 Family (2) Caspase (2) iGluR (2) Reactive Oxygen Species (ROS) (1) Reference Standards (3) Small Interfering RNA (siRNA) (3)
By Research Areas:	Cancer (2) Cardiovascular Disease (2) Inflammation/Immunology (2) Metabolic Disease (1) Neurological Disease (21)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (3)

Inhibitors & Agonists

Peptides

Natural
Products

Antibodies

Oligonucleotides

Targets Recommended: EAAT

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-107522

DL-TBOA 1 Publications Verification	EAAT	Neurological Disease
DL-TBOA is a potent non-transportable inhibitor of excitatory amino acid transporters with IC₅₀s of 70 μM, 6 μM and 6 μM for excitatory amino acid transporter-1 (EAAT1), *EAAT2* and *EAAT3, respectively. DL-TBOA inhibits the uptake of [ ¹⁴C]glutamate in COS-1 cells expressing the human EAAT1* and *EAAT2* with K_i valuesof 42 μM and 5.7 μM, respectively. DL-TBOA blocks *EAAT4* and *EAAT5* in a competitive manner with K_i values of 4.4 μM and 3.2 μM, respectively ^[2] .

HY-100784

Dihydrokainic acid 1 Publications Verification	EAAT	Neurological Disease
Dihydrokainic acid is a glutamate transporters (especially GLT1) inhibitor. Dihydrokainic acid targets GLT1 with high affinity, effectively inhibiting its transport function. Dihydrokainic acid exerts its effect by inhibiting the uptake of glutamate, leading to an increase in extracellular glutamate concentration, thereby affecting neuronal excitability and neurotransmission. Dihydrokainic acid is mainly applied in the field of neuroscience for research on glutamate-related neural functions, epilepsy, learning, and memory ^[2] .

HY-12741

LDN-212320 Maximum Cited Publications 9 Publications Verification LDN-0212320; OSU-0212320	EAAT	Neurological Disease
LDN-212320 (LDN-0212320) is a glutamate transporter (GLT-1)/excitatory amino acid transporter 2 (EAAT2) activator (at translational level). LDN-212320 (LDN-0212320) prevents nociceptive pain by upregulating astroglial GLT-1 expression in the hippocampus and ACC ^[1][2].

HY-107523

WAY-213613 3 Publications Verification	EAAT	Neurological Disease
WAY-213613 is a potent and selective human EAAT2 inhibitor. WAY-213613 has potent EAAT2 inhibitory activity with an IC₅₀ value of 85 nM. WAY-213613 can be used for the research of central nervous system ^[2]

HY-139692

EAAT2 activator 1	EAAT	Neurological Disease
EAAT2 activator 1 is the potent activator of excitatory amino acid transporter 2 (EAAT2). EAAT2 is the major glutamate transporter and functions to remove glutamate from synapses. EAAT2 activator 1 increases EAAT2 protein levels dose-dependently .

HY-114381

GT 949	EAAT	Neurological Disease
GT 949 is a selective excitatory amino acid transporter-2 (EAAT2) positive allosteric modulator with an EC₅₀ of 0.26 nM .

HY-162455

NA-014	EAAT	Neurological Disease
NA-014 is an excitatory amino acid transporter 2 (EAAT2)-selective positive allosteric modulator. NA-014 increases EAAT2-mediated glutamate uptake. NA-014 can be used for the research of epilepsy, neuropathic pain, stroke, drugs of abuse disorders .

HY-107521

TFB-TBOA 3 Publications Verification CF3-Bza-TBOA	EAAT	Neurological Disease
TFB-TBOA (CF3-Bza-TBOA) is a potent glutamate transporter blocker that potently suppresses the activity of glial transporters. TFB-TBOA shows IC₅₀ values of 22, 17, and 300 nM for glutamate transporters EAAT1, EAAT2, and EAAT3 respectively in an uptake assay using cells transiently expressing EAATs .

HY-101310

SYM 2081	iGluR EAAT Bcl-2 Family Caspase	Cardiovascular Disease Neurological Disease Inflammation/Immunology
SYM 2081 is a kainate receptor agonist. SYM 2081 is a substrate of *EAAT1* (K_m of 54 μM). SYM 2081 inhibits *EAAT2*-mediated glutamate transport (K_b is 3.4 μM in Xenopus oocytes), modulates Apoptotic signaling pathways (increases *Bcl-2* and decreases Bax/caspase-3 expression). SYM 2081 exhibits neuroprotective activity. SYM 2081 can be used in the study of hypoxic-ischemic brain damage and inflammatory or neuropathic pain ^[2] .

HY-107523A

WAY-213613 hydrochloride 3 Publications Verification	EAAT	Neurological Disease
WAY-213613 (hydrochloride) is a potent and selective human EAAT2 inhibitor. WAY-213613 has potent EAAT2 inhibitory activity with an IC₅₀ value of 85 nM. WAY-213613 can be used for the research of central nervous system .

HY-168773

(R)-AS-1	EAAT	Neurological Disease
(R)-AS-1 is a selective positive allosteric modulator of the excitatory amino acid transporter 2 (EAAT2), with an EC₅₀ of 11 nM. (R)-AS-1 (at doses of 60 and 90 mg/kg) increases spontaneous locomotor activity in mice. Additionally, it demonstrates anticonvulsant activity in mouse models of seizures induced by maximal electroshock (MES), pentylenetetrazole (PTZ), or electrical stimuli (32 or 44 mA), with ED₅₀s of 66.3, 36.3, 15.6, and 41.6 mg/kg, respectively. (R)-AS-1 can be used in neurological disease research .

HY-146242

SN05	EAAT ASCT	Cancer
SN05 is a potent amino acid transport (AAT) inhibitor with K_i values of 2.77 μM, 0.73 μM, 0.87 μM, 3.7 μM, 7.25 μM, 7.23 μM and 2.22 μM for hASCT1, *rASCT2, hASCT2, EAAT1, EAAT2, EAAC1* and *EAAT5*, respectively. SN05 can be used in the study of cancer .

HY-175296

EAAT2 activator 2	EAAT	Neurological Disease
EAAT2 activator 2 (Compound 4(SF-2)) is a brain-penetrant excitatory amino acid transporter 2 (EAAT2) modulator (K_i=28.7 nM). EAAT2 activator 2 enhances EAAT2-mediated glutamate uptake, improving synaptic glutamate clearance. EAAT2 activator 2 is promising for research of neurodegenerative diseases (e.g., ALS, Alzheimer’s disease) .

HY-100801

L-threo-3-Hydroxyaspartic acid	EAAT	Neurological Disease
L-threo-3-Hydroxyaspartic acid is a potent *EAAT* inhibitor with K_is of 11, 19 and 14 μM for EAAT1, EAAT2 and EAAT3, respectively in HEK293 cell lines .

HY-101227

(±)-threo-3-Methylglutamic acid	EAAT	Metabolic Disease
(±)-threo-3-Methylglutamic acid is a potent *EAAT2/4* inhibitor. (±)-threo-3-Methylglutamic acid also is an ionotropic glutamate receptor agonist. (±)-threo-3-Methylglutamic acid inhibits glutamate uptake by rod outer segments ^[2].

HY-146241

SN40	EAAT ASCT	Cancer
SN40 is a potent amino acid transport (AAT) inhibitor with K_is of 7.29 μM, 2.42 μM, 2.94 μM, 5.55 μM, 24.43 μM and 5.55 μM for rat ASCT2, human ASCT2, EAAT1, EAAT2, EAAC1 and EAAT5, respectively. SN40 can be used for researching anticancer .

HY-162454

DA-023	EAAT	Neurological Disease
DA-023 (Compound 4) is a selective positive allosteric modulator (PAM) of *EAAT2* with an EC₅₀ value of 1 nM .

HY-107522B

DL-TBOA ammonium	EAAT	Neurological Disease
DL-TBOA ammonium is a potent non-transportable inhibitor of excitatory amino acid transporters with IC₅₀s of 70 μM, 6 μM and 6 μM for excitatory amino acid transporter-1 (EAAT1), *EAAT2* and *EAAT3, respectively. DL-TBOA ammonium inhibits the uptake of [ ¹⁴C]glutamate in COS-1 cells expressing the human EAAT1* and *EAAT2* with K_i valuesof 42 μM and 5.7 μM, respectively. DL-TBOA ammonium blocks *EAAT4* and *EAAT5* in a competitive manner with K_i values of 4.4 μM and 3.2 μM, respectively ^[2] .

HY-146241B

SN40 hydrochloride	EAAT ASCT	Others
SN40 hydrochloride is a potent amino acid transport (AAT) inhibitor with K_is of 7.29 μM, 2.42 μM, 2.94 μM, 5.55 μM, 24.43 μM and 5.55 μM for rat ASCT2, human ASCT2, EAAT1, EAAT2, EAAC1 and EAAT5, respectively. SN40 hydrochloride can be used for researching anticancer .

HY-100784R

Dihydrokainic acid (Standard)	Reference Standards EAAT	Neurological Disease
Dihydrokainic acid (Standard) is the analytical standard of Dihydrokainic acid. This product is intended for research and analytical applications. Dihydrokainic acid (DHK) is a glutamate transporter GLT1 (EAAT2) inhibitor. Dihydrokainic acid impairs novel object recognition (NOR) memory performance in mice. Dihydrokainic acid also shows epileptogenic effects .

HY-107523AR

WAY-213613 hydrochloride (Standard)	Reference Standards EAAT	Neurological Disease
WAY-213613 hydrochloride (Standard) is the analytical standard of WAY-213613 (hydrochloride) (HY-107523A). This product is intended for research and analytical applications. WAY-213613 (hydrochloride) is a potent and selective human EAAT2 inhibitor. WAY-213613 has potent EAAT2 inhibitory activity with an IC₅₀ value of 85 nM. WAY-213613 can be used for the research of central nervous system .

HY-183588

HCM-01	EAAT Reactive Oxygen Species (ROS)	Neurological Disease
HCM-01 is an Excitatory amino acid transporter 2 (EAAT2) activator with oral effectiveness and blood-brain barrier penetration.HCM-01 binds to the allosteric site of EAAT2, increases EAAT2 expression in astrocytes, enhances glutamate-handling capacity, and modulates glutamate homeostasis.HCM-01 acts as an antioxidant, improves oxidative/antioxidative balance and increases total antioxidant capacity. HCM-01 can be used for the research of Alzheimer's disease .

HY-182941

Parawixin10	EAAT	Neurological Disease
Parawixin10 (Compound 2) is an N-acylpolyamine. Parawixin10 fails to enhance glutamate uptake in radioligand uptake assays of *EAAT1, EAAT2* or *EAAT3. Parawixin10 exhibits no positive allosteric modulatory activity in radioligand uptake assays of EAAT1−EAAT3*, nor can it improve neuronal survival rates in mice in a dose-dependent and statistically significant manner. Parawixin10 has no neuroprotective activity .

HY-RS13053

Slc1a2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Slc1a2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Slc1a2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Slc1a2 Rat Pre-designed siRNA Set A Slc1a2 Rat Pre-designed siRNA Set A

HY-RS13051

SLC1A2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
SLC1A2 Human Pre-designed siRNA Set A contains three designed siRNAs for SLC1A2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

SLC1A2 Human Pre-designed siRNA Set A SLC1A2 Human Pre-designed siRNA Set A

HY-RS13052

Slc1a2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Slc1a2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Slc1a2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Slc1a2 Mouse Pre-designed siRNA Set A Slc1a2 Mouse Pre-designed siRNA Set A

HY-101310R

SYM 2081 (Standard)	iGluR Reference Standards EAAT Bcl-2 Family Caspase	Cardiovascular Disease Neurological Disease Inflammation/Immunology
SYM 2081 (Standard) is the analytical standard of SYM 2081 (HY-101310). This product is intended for research and analytical applications. SYM 2081 is a kainate receptor agonist. SYM 2081 is a substrate of EAAT1 (Km of 54 μM). SYM 2081 inhibits EAAT2-mediated glutamate transport (Kb is 3.4 μM in Xenopus oocytes), modulates Apoptotic signaling pathways (increases Bcl-2 and decreases Bax/caspase-3 expression). SYM 2081 exhibits neuroprotective activity. SYM 2081 can be used in the study of hypoxic-ischemic brain damage and inflammatory or neuropathic pain ^[2] .

HY-100838

cis-α-(Carboxycyclopropyl)glycine L-CCG III	EAAT	Neurological Disease
cis-α-(Carboxycyclopropyl)glycine (L-CCG III) is a potent, competitive glutamate uptake inhibitor. cis-α-(Carboxycyclopropyl)glycine is a substrate of glutamate transporters (GluT) (EC₅₀: 13 μM, 2 μM for EAAT 1 and EAAT 2, respectively). cis-α-(Carboxycyclopropyl)glycine inhibits a Na ⁺-dependent high-affinity L-glutamate uptake in glial plasmalemmal vesicles (GPV) and synaptosomes ^[2].

Cat. No.	Product Name	Target	Research Area

HY-100838

cis-α-(Carboxycyclopropyl)glycine L-CCG III	EAAT	Neurological Disease
cis-α-(Carboxycyclopropyl)glycine (L-CCG III) is a potent, competitive glutamate uptake inhibitor. cis-α-(Carboxycyclopropyl)glycine is a substrate of glutamate transporters (GluT) (EC₅₀: 13 μM, 2 μM for EAAT 1 and EAAT 2, respectively). cis-α-(Carboxycyclopropyl)glycine inhibits a Na ⁺-dependent high-affinity L-glutamate uptake in glial plasmalemmal vesicles (GPV) and synaptosomes ^[2].

L-threo-3-Hydroxyaspartic acid	Human Gut Microbiota Metabolites Microorganisms Endogenous metabolite Source Classification	EAAT
L-threo-3-Hydroxyaspartic acid is a potent *EAAT* inhibitor with K_is of 11, 19 and 14 μM for EAAT1, EAAT2 and EAAT3, respectively in HEK293 cell lines .

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P82737

	EAAT2 Antibody (YA2482) Excitatory amino acid transporter 2; Glutamate/aspartate transporter II; Sodium-dependent glutamate/aspartate transporter 2; Solute carrier family 1 member 2	WB, IP	Human, Mouse, Rat
	EAAT2 Antibody (YA2482) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to EAAT2.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Slc1a2 Rat Pre-designed siRNA Set A		siRNAs Rat Pre-designed siRNA Sets
Slc1a2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Slc1a2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

SLC1A2 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
SLC1A2 Human Pre-designed siRNA Set A contains three designed siRNAs for SLC1A2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Slc1a2 Mouse Pre-designed siRNA Set A		siRNAs Mouse Pre-designed siRNA Sets
Slc1a2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Slc1a2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks